PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 18, 2026Internal Medicine0 citationsOpen Access

A Delayed Progression of Porphyria-Associated Kidney Disease After Hemin Therapy in a Patient with Acute Intermittent Porphyria: A Case Report

TITakuya IshimuraKWKen JC WellsASArisa Shimada

Key Points

  • To explore the effects of hemin therapy on kidney function in a patient with acute intermittent porphyria and associated kidney disease.
  • Administered hemin therapy to a 50-year-old female patient with acute intermittent porphyria having recurrent abdominal pain and kidney injury.
  • Monitored renal function through estimated glomerular filtration rate assessments before and after therapy.
  • Hemin treatment reduced the frequency of porphyria attacks as well as the decline in estimated glomerular filtration rate.
  • Despite eventual progression to end-stage kidney disease, hemin significantly slowed the renal function decline.

Abstract

Acute intermittent porphyria (AIP) is a condition characterized by the neurotoxic accumulation of δ-aminolevulinic acid and porphobilinogen. However, chronic kidney disease is an under-recognized complication. A 50-year-old woman experienced recurrent abdominal pain with repeated acute kidney injury and hyponatremia, resulting in a rapid decline in renal function. Marked elevations of both metabolites, as well as her genetic mutation, confirmed AIP. The administration of hemin markedly decreased the frequency of porphyria attacks and significantly attenuated the annual estimated glomerular filtration rate decline. Although the patient eventually developed end-stage kidney disease, hemin treatment slowed the progression of renal failure.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ishimura et al. (2026) studied this question.

synapsesocial.com/papers/6a0aac6d5ba8ef6d83b6fc86https://doi.org/10.2169/internalmedicine.7131-26
Ask AI
Helpful
Bookmark
Share
View Full Paper